Gold certification for new DZNE building in Bonn: The first laboratory building receives the highest award in Germany
Today, January, 15th, 2019, the new DZNE building in Bonn is awarded the “Gold…
Research grant for Munich DZNE scientist
Dr. Sabina Tahirovic from the DZNE site in Munich received funding from the Alzheimer Forschung Initiative e. V. (AFI), at a ceremony in Wiesbaden on January…
Job offers
The DZNE offers a wide range of career opportunities for scientists, management and administration professionals. We promote targeted personal development and all our centres offer…
Alzheimer‘s: Therapy must begin as early as possible
Protein plaques in the brain are the cause of Alzheimer's disease and the starting point for possible therapies. At later stages, however,…
Thanks to laboratory produced human mini-retinas, researchers were able to observe complex changes in the retina as they occur in macular degeneration.
Thanks to laboratory produced human…
Areas of investigation/research focus
Monclonal antibodies are valuable reagents to study molecular mechanisms of the neurodegenerative diseases Alzheimer disease (AD), amyotrophic lateral…
The chain of setbacks in previous trials began in 2014 with the drug gantenerumab, followed by crenezumab, solanezumab and aducanumab. The failed attempts, each involving multi-million dollar…
Highly Cited: Several DZNE Scientists Among the World’s Most Influential Researchers
Researchers whose studies are widely quoted in scientific journals are considered influential – because a…
Welcome to our website, here you can inform yourself basically cookie-free.
We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.
